Details for Patent: 6,369,062
✉ Email this page to a colleague
Title: | Sustained release ranolazine formulations |
Abstract: | A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL. |
Inventor(s): | Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dunfermline, GB), Langridge; John (Wrexham, GB) |
Assignee: | CV Therapeutics, Inc. (Palo Alto, CA) Syntex (USA) Inc. (Palo Alto, CA) |
Filing Date: | Mar 29, 2000 |
Application Number: | 09/538,337 |
Claims: | 1. A compressed tablet consisting essentially of from about 70 to about 80 wt % ranolazine, from about 5 to about 12.5 wt % methacrylic acid copolymer, from about 1 to about 3 wt % hydroxypropyl methylcellulose, microcrystalline cellulose, sodium hydroxide, and magnesium sterate, wherein the compressed tablet includes from about 350 to about 800 mg ranolazine. |